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Background
The emotional impact of genetic testing has been exten-
sively studied in individuals at high risk for Hereditary
Breast and Ovarian Cancer Syndrome (HBOS). Studies
on the impact of genetic testing for Lynch Syndrome
(LS) are not as prevalent and few studies have compared
the two cohorts.
Purpose
To compare the psychological impact of genetic testing
in participants at high risk for LS and HBOS and iden-
tify variables associated with genetic testing distress,
anxiety and depression at one week and one year post
disclosure of genetic test results.
Methods
140 individuals undergoing genetic testing for LS and
133 undergoing genetic testing for HBOS at the Dana-
Farber Cancer Institute were enrolled in a longitudinal
questionnaire study. We assessed levels of genetic test-
ing distress, anxiety and depression using The Multidi-
mensional Impact of Cancer Risk Assessment (MICRA)
and the Hospital Anxiety and Depression Scale (HADS).
Multivariable regression analysis was used to identify
factors associated with psychological distress in the LS
and HBOS cohorts. One year follow-up data is based on
96 LS and 94 HBOS tested individuals that completed
the one year questionnaire.
Results
For both cohorts, individuals who had the expectation
for carrying a deleterious gene pre-test and/or those
who received a positive or variant of uncertain signifi-
cance (VUCS) test result had significantly higher genetic
testing distress at one week post-disclosure (p ≤ 0.05).
Additional independent predictors of higher genetic
testing distress in the LS cohort included not being mar-
ried and having a personal history of cancer. In the
HBOS cohort, predictors included having a higher
HADS anxiety score at baseline and having an annual
household income of ≤ $50,000.
At one year post-disclosure, individuals that tested
positive or VUCS and/or had the expectation of carrying
a deleterious gene pre-test continued to have signifi-
cantly higher genetic testing distress (p ≤ 0.01). While
there were no differences between the cohorts in base-
line or post-disclosure HADS anxiety or depression
scores, significantly more individuals in the LS cohort
had HADS depression scores ≥ 8 one year after testing
(17% vs. 5%; p= 0.05).
Conclusion
Individuals at risk for LS and HBOS whose genetic tests
reveal a pathogenic mutation or VUCS can continue to
demonstrate genetic testing distress one year after
receiving genetic test results. These individuals may
benefit from counseling beyond the immediate disclo-
sure period.
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